Cambridge Isotope Laboratories, Inc. Expands 13C Production Capacity With North Star Project
5.9.2024 09:00:00 CEST | ACCESS Newswire | Press release
TEWKSBURY, MA / ACCESSWIRE / September 5, 2024 / Cambridge Isotope Laboratories, Inc. (CIL), the global leader in 13Cand 13C urea production, is excited to announce the startup of its North Star project, significantly increasing the company's production capabilities.
CIS Aerial
CIS Aerial
The North Star project commenced in mid-2020 as the world's largest 13C production cascade. After the complex build of phase one finished in March 2024, CIL began to introduce naturally abundant product into the front end of the distillation cascade. With each stage of the cascade, the predicted enrichment has exceeded expectations, and the overall performance has been exceptional. The first highly enriched 13C finished product will be captured in October of 2024. CIL will build more front-end systems to bring final production of the cascade to world scale capacities by April 2025.
"This is CIL's fourth 13C production system since 1990. With each system, our team of talented engineers have incorporated their 30-plus years of design, operation, and construction experience into the next system. Our North Star cascade is certainly proving that knowledge and experience pays impactful dividends for CIL and our customers," said Cliff Caldwell, CEO of CIL.
"CIL's talented organic chemists incorporate our 13C product into a myriad of labelled organic compounds with significant importance in environmental testing, biopharmaceutical research, and medical diagnostics. One critical product is 13C Urea used in the detection of H-pylori infections in humans. H-pylori is widespread throughout the world and can lead to stomach ulcers and stomach cancer. 13C urea provides a low-cost detection method to allow for treatment and elimination of H-pylori. The North Star project assures CIL's commitment to meeting the needs of 13C urea and accommodate future growth in other critical applications," states Mike Steiger, Vice President of Engineering and Project Execution.
For years, CIL has been the go-to expert in cryogenic distillation, solidifying its position as the world's top producer of 13C isotopes. CIL's customers can be assured they have the reliable capacity of 13C to meet enable the commercialization of their research.
About Cambridge Isotope Laboratories, Inc.
CIL is the world's largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL subsidiary ABX, located in Dresden, Germany, is active in the development and commercialization of radio isotopic-labeled compounds for the diagnosis and treatment of cancers. CIL is an operating business owned by Otsuka Pharmaceutical. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL China; CIL Canada; ABX in Dresden, Germany; and Eurisotop in Saclay, France. For more information on CIL, visit isotope.com.
Contact Information
Crissy Krisko
crissyk@isotope.com
1.978.269.1930
SOURCE: Cambridge Isotope Laboratories, Inc.
View the original press release on newswire.com.
Cambridge Isotope Laboratories, Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Aminona Capital Partners Closed Second Latam Real Estate Fund11.5.2026 14:55:00 CEST | Press release
ZURICH, SWITZERLAND / ACCESS Newswire / May 11, 2026 / Aminona Capital Partners have successfully advised and partnered on closing a second South and Central America residential and commercial real estate fund which specifically targets large scale real estate opportunities in the region. Co-founders Nicolas Jenik and Phillip Morelle are very optimistic about the real estate prospects in Latin America, specifically in countries such as Argentina, Chile, Colombia and Venezuela which are already showing large returns and projected to continue growing. With a vast network on the ground in the region and deep knowledge of market dynamics in the Latin American real estate sector, Aminona Capital Partners are able to bring added value to investors and maximising returns. The plan is now to roll out a third real estate fund in the near future targeting the same region using the same opportunity driven strategy of pursing added value transactions, development repositioning, well financed const
Frame Security Launches with $50M to Build the Future of Human Security11.5.2026 14:05:00 CEST | Press release
Backed by Index Ventures, Team8, and Picture Capital, Frame is launching an AI-driven platform designed to help organizations defend against the growing wave of AI-powered social engineering and deepfake attacks by empowering employees to be the strongest line of defense NEW YORK CITY, NY / ACCESS Newswire / May 11, 2026 / Frame Security, today announced its public launch alongside a $50 million funding round led by Index Ventures, Team8, and Picture Capital, with participation from industry heavyweights Wiz CEO Assaf Rappaport and Elad Gil, who initially joined as an angel investor and has since doubled down through his fund, Gil Capital. The company is building a new category of human risk security, designed to protect organizations against the largest attack vector in cybersecurity: people. Nearly 96% of organizations provide some form of security awareness training, yet roughly 90% of data breaches still involve the human element. As a result, organizations are investing heavily in
TruMerit and Credivera Issue First Verifiable Digital Credentials for Global Healthcare Professionals8.5.2026 16:00:00 CEST | Press release
PHILADELPHIA, PA / ACCESS Newswire / May 8, 2026 / TruMerit, a global leader in healthcare workforce development and credential verification, today announced that it has issued its first verifiable digital credentials to healthcare professionals through a new partnership with Credivera, marking a major step forward in secure, portable credential verification for the global healthcare workforce. The first group of digital credentials has been awarded to nurses and other healthcare professionals who successfully passed TruMerit's global certification examinations over the last year. These include the Certified Global Nurse credential and credentials tailored for nurses and other healthcare workers specializing in rehabilitation care. These secure credentials can now be stored, managed, and shared digitally, allowing employers, regulators, and licensing authorities to instantly verify professional qualifications. Through Credivera's secure credential exchange platform, TruMerit credential
MicroVision and Avular Collaborate to Advance Autonomous Sensing and Drone Integration for Next-Generation Infrastructure Applications7.5.2026 22:05:00 CEST | Press release
Integrated lidar and modular drone platforms enable scalable autonomy, mapping, and navigation across complex real-world environments REDMOND, WA AND EINDHOVEN, THE NETHERLANDS / ACCESS Newswire / May 7, 2026 / MicroVision, Inc., (Nasdaq:MVIS), a leader in advanced perception solutions, today announced the signing of a Memorandum of Understanding (MoU) with Avular Innovations B.V. to integrate their technologies and accelerate the development of next-generation autonomous systems for civil infrastructure and global commercial applications. By combining MicroVision's high-performance, solid-state lidar, optimized for reduced energy usage and increased operational efficiency, with Avular's modular drone platforms and system integration expertise, the companies are creating a flexible, scalable solution designed to address real-world operational challenges across global markets. The collaboration focuses on delivering advanced capabilities, including autonomous mission execution in GPS-de
Innodata Reports Record First Quarter 2026 Results7.5.2026 22:05:00 CEST | Press release
Revenue Up 54% Year-Over-Year, Beats Consensus by 18% Adjusted EBITDA of $25.0 Million Beats Consensus by 139%; Adjusted Gross Margin Expands to 47% Raises Full-Year 2026 Revenue Growth Guidance to ~40% or More, Up From ~35% or More Announces New Engagements With Big Tech Company Expected to Generate Approximately $51 Million of Revenue in 2026 NEW YORK, NY / ACCESS Newswire / May 7, 2026 / INNODATA INC. (Nasdaq:INOD) today reported results for the first quarter ended March 31, 2026. Revenue of $90.1 million, representing 54% year-over-year revenue growth. Adjusted Gross Profit of $42.6 million, representing Adjusted Gross Margin of 47%.* Adjusted EBITDA of $25.0 million, or 28% of revenue, an increase of $12.3 million from $12.7 million in the same period last year.* Net income of $14.9 million, or $0.46 per basic share and $0.42 per diluted share, compared to net income of $7.8 million, or $0.25 per basic share and $0.22 per diluted share, in the same period last year. Cash, cash equ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom